Clinical observation on effect of compound E-bei ointment in treating plaque psoriasis.
- Author:
Ping SONG
1
;
Zhi-fang YAN
;
Xian XU
Author Information
- Publication Type:Journal Article
- MeSH: Administration, Cutaneous; Adolescent; Adult; Aged; Drugs, Chinese Herbal; administration & dosage; therapeutic use; Female; Humans; Male; Middle Aged; Ointments; Phytotherapy; Psoriasis; drug therapy; pathology; Skin; drug effects; pathology; Treatment Outcome; Young Adult
- From: Chinese Journal of Integrated Traditional and Western Medicine 2007;27(4):352-354
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo observe the efficacy oand safety of Compound E-Bei ointment (CEBO) in treating plaque psoriasis.
METHODSAdopting block-randomized, open, positive Western medicine and placebo parallel group controlled method, a total of 120 enrolled patients were administered orally with Saoxuan Pill, and randomized into three groups respectively treated with external application of CEBO, Daivonex, or vehicle control twice a day for 4 weeks. The changes of erythema, infiltration, scaly eruption, pruritus and the area of lesion were evaluated, the safety and the initiating time of symptom improvement (ITSI) were observed as well.
RESULTSObservation on local lesion showed that the scores of erythema, infiltration, scaly eruption, pruritus were significantly improved in difference between the CEBO group and the Daivonex group (P < 0.01). But in the placebo control group, significant improvement was only shown in scaly eruption scores (P < 0.01), so, the improvement in skin lesion in the placebo group was significantly inferior to that in the other two groups (P < 0.01). The ITSI of pruritus was shorter in CEBO group than that in the Daivonex group and the placebo group (P < 0.01), but that of other symptoms showed insignificant difference between the CEBO group and the Daivonex group, as for comparing in ITSI of erythema, infiltration, scaly eruption and pruritus, it was significantly shorter in the CEBO group and Daivonex group than that in the placebo group respectively (P < 0.01). The occurrence of adverse events in the CEBO group had insignificant difference to that in the Daivonex group, but the recurrence rate in the former was significantly lower than that in the latter (P < 0.05).
CONCLUSIONCEBO can effectively improve the symptoms of skin lesion in patients with plaque psoriasis, the clinical efficacy is not inferior to that of positive Western medicine.